
|Articles|December 1, 2002
Anecortave acetate administration shows promise for subfoveal, exudative AMD
San Francisco-The angiostatic steroid anecortave acetate continues to show promise as a safe and effective treatment for subfoveal, exudative age-related macular degeneration (AMD), according to results from an interim analysis of an ongoing phase II trial.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
DAYBREAK: Tarcocimab, tabirafusp-ted noninferior to aflibercept in wet AMD
2
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
3
Myopia-related retinal detachments in younger patients: A retina view
4
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
5












